TEST:

TNBCType-IM assay

Here, we focus on the evolution of TNBCtype after NACT and its prognostic value. We present a prospective cohort of stage I-III TNBC patients from 10 hospitals across Spain and Peru, treated with 6 cycles of NACT with carboplatin and docetaxel (NCT01560663). TNBCtype significantly differs after exposure to NACT and subtyping of the RD enables a more accurate prognostic classification.

We report, to our knowledge, for the first time that the TNBC molecular subtype and IM signature frequently change after NST. Our results also suggest that EMT is promoted by NST. Our findings may lead to innovative adjuvant therapy strategies in TNBC cases with residual tumor after NST.

Conclusion Identification of AR driven tumors within TNBC has both prognostic and predictive utility. Methods using limited number of AR regulated genes could be easily applied to larger BC cohorts to identify TNBC tumours driven by AR signalling and may respond well to anti-androgen therapies.

"Peer reviewed research demonstrates the utility of the Oncocyte’s TNBCType-IM assay to identify the most suitable cell lines to help biopharma and academic researchers in their quest for treatments for TNBC, the deadliest form of breast cancer. . Published research demonstrates the test’s ability to work consistently both in vitro and in vivo in six cell lines used in drug development, suggesting promise in research applications."